Ankie M Harmsze

Summary

Publications

  1. ncbi CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study
    Ankie M Harmsze
    Department of Clinical Pharmacy, St Antonius Hospital, PO Box 2500, Nieuwegein 3430 EM, The Netherlands
    Eur Heart J 31:3046-53. 2010
  2. ncbi Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting
    Heleen J Bouman
    Department of Cardiology, St Antonius Hospital, CM Nieuwegein, The Netherlands
    Heart 97:1239-44. 2011
  3. ncbi The influence of CYP2C19*2 and *17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting
    Ankie M Harmsze
    St Antonius Center for Platelet Function Research, St Antonius Hospital, Nieuwegein, The Netherlands
    Pharmacogenet Genomics 22:169-75. 2012
  4. ncbi High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention
    Nicoline J Breet
    Department of Cardiology, St Antonius Hospital, Nieuwegein, The Netherlands
    Heart 97:983-90. 2011
  5. ncbi Sulfonylureas and on-clopidogrel platelet reactivity in type 2 diabetes mellitus patients
    Ankie M Harmsze
    Department of Clinical Pharmacy, St Antonius Hospital, Nieuwegein, The Netherlands
    Platelets 22:98-102. 2011
  6. ncbi The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response
    Ankie M Harmsze
    Department of Clinical Pharmacy, St Antonius Hospital, P O Box 2500, 3430 EM Nieuwegein, The Netherlands
    Thromb Haemost 103:920-5. 2010
  7. ncbi Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation
    Nicoline J Breet
    Department of Cardiology, St Antonius Hospital, PO Box 2500, 3435 CM Nieuwegein, The Netherlands
    JAMA 303:754-62. 2010

Collaborators

  • Johannes C Kelder
  • Hugo ten Cate
  • Nicoline J Breet
  • Heleen J Bouman
  • Jurrien M ten Berg
  • Jochem W van Werkum
  • Christian M Hackeng
  • Th O Bergmeijer
  • Vera H M Deneer
  • Egbert T Bal
  • Henk J T Ruven
  • Jan A S van der Heyden
  • Benno J W M Rensing
  • Maarten J Suttorp
  • Vera H Deneer

Detail Information

Publications7

  1. ncbi CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study
    Ankie M Harmsze
    Department of Clinical Pharmacy, St Antonius Hospital, PO Box 2500, Nieuwegein 3430 EM, The Netherlands
    Eur Heart J 31:3046-53. 2010
    ....
  2. ncbi Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting
    Heleen J Bouman
    Department of Cardiology, St Antonius Hospital, CM Nieuwegein, The Netherlands
    Heart 97:1239-44. 2011
    ....
  3. ncbi The influence of CYP2C19*2 and *17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting
    Ankie M Harmsze
    St Antonius Center for Platelet Function Research, St Antonius Hospital, Nieuwegein, The Netherlands
    Pharmacogenet Genomics 22:169-75. 2012
    ....
  4. ncbi High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention
    Nicoline J Breet
    Department of Cardiology, St Antonius Hospital, Nieuwegein, The Netherlands
    Heart 97:983-90. 2011
    ..The aim of the present study was to determine the incidence of dual high on-treatment platelet reactivity (DAPR) and its impact on clinical outcome...
  5. ncbi Sulfonylureas and on-clopidogrel platelet reactivity in type 2 diabetes mellitus patients
    Ankie M Harmsze
    Department of Clinical Pharmacy, St Antonius Hospital, Nieuwegein, The Netherlands
    Platelets 22:98-102. 2011
    ..7, p=0.048). Concomitant treatment with sulfonylureas might be associated with decreased platelet inhibition by clopidogrel in type 2 diabetes mellitus patients on dual antiplatelet therapy undergoing elective coronary stent implantation...
  6. ncbi The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response
    Ankie M Harmsze
    Department of Clinical Pharmacy, St Antonius Hospital, P O Box 2500, 3430 EM Nieuwegein, The Netherlands
    Thromb Haemost 103:920-5. 2010
    ..Only amlodipine was associated with clopidogrel poor-response. The drug-drug interaction between clopidogrel and amlodipine might be more clinically relevant as compared to P-glycoprotein-inhibiting CCBs...
  7. ncbi Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation
    Nicoline J Breet
    Department of Cardiology, St Antonius Hospital, PO Box 2500, 3435 CM Nieuwegein, The Netherlands
    JAMA 303:754-62. 2010
    ..None of the tests provided accurate prognostic information to identify patients at higher risk of bleeding following stent implantation. Trial Registration clinical trials.gov Identifier: NCT00352014 [corrected]...